



# REPRIEVE



## Randomized Trial to Prevent Vascular Events in HIV October 2023 Table of Contents

- [Forthcoming Study Closure Deadlines](#)
- [Tips From the Data Management Center](#)
- [Deadline to Ship Specimens](#)
- [Study Closure FAQ](#)
- [REPRIEVE Community Forums: Slides and Recordings Now Available!](#)
- [Webpage to Support REPRIEVE Results Dissemination](#)
- [Check out the REPRIEVE Feature in The Washington Post!](#)
- [Join Us for the Next Team/Site Call Tuesday October 17th](#)
- [Are You Up to Date?](#)



### ***Forthcoming Study Closure Deadlines***

- **October 16th, 2023: Deadline for site responses and corrections to clinical database**
- October 16th, 2023: eCRF sign-off by site investigators initiated (training will be provided during October 17th Team/Site Call)
- November 13th, 2023: eCRF sign-off by site investigators complete
- November 13th, 2023: Clinical database closure/data freeze





## Tips From the Data Management Center

As we approach the October 16<sup>th</sup> deadline for site responses and corrections to the REPRIEVE database, our data team is working to ensure that REPRIEVE data is as complete, accurate, and up-to-date as possible. Therefore, ***please resolve any outstanding queries your site/lab may have as soon as possible.***

**Click here** to download slides on resolving queries in OpenClinica, or go to the FSTRF YouTube channel to access an instructional video **here**.

If your lab has received queries, they will be sent via email. Do not respond to the email notification. The email indicates that you need to log into the DMC Portal under the REPRIEVE Project and review the laboratory query in the Query System.

**Click here** to download more detailed guidance about Laboratory Queries.

If you encounter a problem or need help using the Laboratory Query system contact LDMS User Support at [ldmshelp@fstrf.org](mailto:ldmshelp@fstrf.org) or +1 716 834-0900 x7311.



## Deadline to Ship Specimens From Site Labs to BRI Was September 18, 2023

If your site has not yet shipped or is experiencing shipping delays, please reach out to the REPRIEVE Lab Committee as soon as possible ([reprieve.labcom@fstrf.org](mailto:reprieve.labcom@fstrf.org)).

Any further delays in shipping could lead to these specimens being unavailable to send to the testing lab and therefore would not be included in future REPRIEVE analyses.

If you are at a non-ACTG site in the US or Canada and need a shipping label, please email [mghreprieveshipping@partners.org](mailto:mghreprieveshipping@partners.org). Please reach out to BRI ([brirepository@afbr-bri.org](mailto:brirepository@afbr-bri.org)) to alert them of an upcoming shipment to confirm they are able to receive it.



**Q.** When can I close the REPRIEVE (A5332) protocol with my local IRB/EC?

**A.** The REPRIEVE study closure SOP indicates that study closure with the site's IRB/EC is to be completed after unblinding (November 20th, 2023). Deregistration of the protocol with DAIDS protocol registration is to occur *after* confirmation of study closure with the site's IRB/EC (January 1, 2024).



## REPRIEVE Community Forums: Slides and Recordings Now Available!

REPRIEVE has hosted two community forums in English and Spanish to review the trial results. If any participants at your site were unable to attend but would like to learn more, presentation slides and recordings of the forums are posted on the REPRIEVE website: <https://www.reprievetrial.org/participants/community-forum/>.

If your site is interested or planning to host a community forum about REPRIEVE, we would be happy to support your site and provide presentation materials. Please reach out to Katie ([kfitch@mgh.harvard.edu](mailto:kfitch@mgh.harvard.edu)) and Marissa ([mdiggs@mgh.harvard.edu](mailto:mdiggs@mgh.harvard.edu)) at the REPRIEVE CCC.



## Webpage to Support REPRIEVE Results Dissemination

The REPRIEVE CCC is developing a webpage, which will be a central location where a variety of REPRIEVE results materials are posted. These materials include a graphical abstract of the trial results, statin guidance for participants and providers, participant FAQs, and more!

Keep an eye out for this new page on the REPRIEVE website: <https://www.reprievetrial.org/>.

The Washington Post



## Check out the REPRIEVE Feature in The Washington Post!

On October 2nd, The Washington Post featured REPRIEVE in an article titled "For people with HIV, statins show 35 percent drop in heart attack risk."

This article was part of The Post's "Big Number" series, which briefly examines the statistical aspects of health issues. [Click here](#) to access the article.

Please share these links with REPRIEVE participants, clinicians, and the HIV community in your area.

For more news updates, please refer to the REPRIEVE website:

<https://www.reprievetrial.org/learnmore/news/>.



## Join Us for the Next Team/Site Call Tuesday October 17th

If you have any questions in advance of the site call we'd love to hear from you! Please email them to [Katie Fitch](#) at the REPRIEVE CCC.

***Note that REPRIEVE will continue to hold monthly site calls during study closure to share important updates and answer any questions sites may have.***

12:00 PM PERU (PET)  
1:00 PM US (EDT)  
1:00 PM HAITI (EDT)  
1:00 PM PUERTO RICO (AST)  
2:00 PM BRAZIL (BRT)  
7:00 PM BOTSWANA (CAT)\*\*\*  
7:00 PM SOUTH AFRICA (SAST)\*\*\*

7:00 PM ZIMBABWE (CAT)\*\*\*

8:00 PM UGANDA (EAT)\*\*\*

10:30 PM INDIA (IST)\*\*\*

12:00 AM (May 17th 2023) THAILAND (ICT)\*\*\*

\*\*\*We do not expect site staff to join these calls during their off-work hours. Instead, we will post slides from this call on the A5332 PSWP.

Remember that questions are always welcome at [actg.corea5332@fstrf.org](mailto:actg.corea5332@fstrf.org)

## **REPRIEVE (A5332): Are You Up to Date?**

**For A5332 please use:**

*Protocol Version 6.0 dated 05/16/2022*

*MOPS Version 6.0 dated 12/14/2022*

*LPC for ACTG Sites Version 6.0 dated 06/03/2022*

*LPC for Non-ACTG Sites Version 6.0 dated 09/08/2022*

*FAQs dated 09/02/2022*

*Coenrollment Guidelines dated 02/06/2023*

*These documents are on the [A5332 PSWP](#)*

***For future reference, all newsletters are available on the  
[REPRIEVE Website](#)***

*We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at [reprieve.news@fstrf.org](mailto:reprieve.news@fstrf.org).*



**Like, comment, share, and retweet!**

### ***REPRIEVE Trial Clinical Coordinating Center***

Massachusetts General Hospital

55 Fruit Street, 5LON 207

Boston, MA USA 02114

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).

---

This email was sent to [mdiggs@mgh.harvard.edu](mailto:mdiggs@mgh.harvard.edu)  
[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)  
Massachusetts General Hospital · 5 Longfellow Place · Boston, MA 02214 · USA

